KBY Biotech Indexv0.0.34
Search
← Pipeline|Teralucimab

Teralucimab

Approved
MRK-9763
By Marker Therapeutics
Source: Trial-derived·Trials: 1
Modality
Vaccine
MOA
CDK4/6i
Target
SMN2
Pathway
STING
MDDADPKD
Development Pipeline
Preclinical
~Mar 2015
→ ~Jun 2016
Phase 1
~Sep 2016
→ ~Dec 2017
Phase 2
~Mar 2018
→ ~Jun 2019
Phase 3
~Sep 2019
→ ~Dec 2020
NDA/BLA
~Mar 2021
→ ~Jun 2022
Approved
Sep 2022
→ May 2026
ApprovedCurrent
NCT03953076
1,501 pts·ADPKD
2022-09→2026-05·Completed
1,501 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2026-05-192mo awayPh3 Readout· ADPKD
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2
Approved
Complet…
Catalysts
Ph3 Readout
2026-05-19 · 2mo away
ADPKD
Completed|StartCompletionToday
Trials (1)
NCTPhaseIndicationStatusNEP
NCT03953076ApprovedADPKDCompleted1501CR
Competitors (10)
DrugCompanyPhaseTargetMOA
PFE-5767PfizerPhase 1/2BETCDK4/6i
RHH-1969RocheApprovedBETCDK4/6i
IvocapivasertibBristol-Myers SquibbPhase 1BETCDK4/6i
ZorimavacamtenBristol-Myers SquibbPreclinicalCl18.2CDK4/6i
NVO-6275Novo NordiskPhase 1SMN2BTKi
FixatenlimabGSKPhase 1/2JAK1CDK4/6i
TAK-5300TakedaPhase 1SMN2AuroraAi
GIL-2259Gilead SciencesApprovedSMN2CAR-T CD19
REG-647RegeneronPreclinicalSMN2SOS1i
VRT-4938Vertex PharmaPreclinicalHER2CDK4/6i